As of June 17, 2025, GSK plc (GSK.L) reports a EV/EBITDA of 9.61.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing GSK plc's EV/EBITDA to Peers
To better understand GSK plc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| GSK plc (GSK.L) | 9.61 |
| Karo Pharma AB (KARO.ST) | 305.92 |
| Dechra Pharmaceuticals PLC (DPH.L) | 32.10 |
| Financiere de Tubize SA (TUB.BR) | 31.45 |
| ALK-Abello A/S (ALK B.CO) | 24.56 |
| Orion Oyj (ORNBV.HE) | 20.50 |
Compared to its competitors, GSK plc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.